Maher VE, Fernandes LL, Weinstock C, et al. - Among patients with urothelial cancer treated with anti–programmed death protein 1 or ligand 1 (anti–PD-1/L1) antibodies, researchers evaluated the connection among tumor response rate, overall survival, and the development of related adverse events of special interest (AESIs) or related immune-mediated adverse events (imAEs; defined as AESIs treated with topical or systemic corticosteroids). In 1,747 patients with metastatic or locally advanced urothelial cancer, they analyzed seven trials that culminated in the approval of an antibody anti-PD-1/L1. According to the findings, patients who responded to anti-PD-1/L1 treatment were more likely to report a related AESI or imAE. This association did not appear to be due to the increased exposure time in patients who responded. The duration of response was not influenced by systemic corticosteroid use.